Anzeige
Mehr »
Samstag, 07.06.2025 - Börsentäglich über 12.000 News
Starke Zahlen: EBITDA bei 9 Mio.?€ - Startet jetzt die Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A412AD | ISIN: US83006G4010 | Ticker-Symbol:
NASDAQ
06.06.25 | 22:00
2,920 US-Dollar
-1,35 % -0,040
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
60 DEGREES PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
60 DEGREES PHARMACEUTICALS INC 5-Tage-Chart

Aktuelle News zur 60 DEGREES PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
FrRedChip Companies, Inc.: 60 Degrees Pharmaceuticals and Liberty Star Interviews to Air on the RedChip Small Stocks, Big Money Show on Bloomberg TV369ORLANDO, FL / ACCESS Newswire / June 6, 2025 / RedChip Companies will air interviews with 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP) and Liberty Star Minerals (OTCQB:LBSR) on the RedChip Small Stocks...
► Artikel lesen
Mi60 Degrees Pharmaceuticals introduces new malaria drug packaging1
Mi60 Degrees Pharmaceuticals Expands Options for Malaria Prevention with Introduction of ARAKODA (tafenoquine) 8-Count Bottle Format62New 8-count bottles now available through major retail pharmaciesARAKODA® is the only weekly prophylactic therapy to provide protection against the blood and liver stages of malaria WASHINGTON, June...
► Artikel lesen
DiSixty Degrees Pharmaceuticals: Babesiosis Incidence in U.S. 10x Higher Than CDC Estimates, According to Insurance Claims Study Commissioned by 60 Degrees Pharmaceuticals8125,000 U.S. adults per year claim reimbursement for medical costs associated with babesiosis v. CDC estimates of 2,000A full 45 percent of persistent babesiosis cases include chronic fatigueHealthcare...
► Artikel lesen
MoAscendiant Capital lowers 60 Degrees stock price target to $71
16.05.60 Degrees Pharmaceuticals GAAP EPS of -$1.561
60 DEGREES PHARMACEUTICALS Aktie jetzt für 0€ handeln
15.05.60 Degrees Pharmaceuticals Announces First Quarter 2025 Results76Q1 2024 net product revenues increased 55% year-over-year to $163.6 thousand.Gross profit increased 124% to $90.3 thousand. WASHINGTON, May 15, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals...
► Artikel lesen
15.05.60 DEGREES PHARMACEUTICALS, INC. - 10-Q, Quarterly Report1
22.04.60 Degrees Pharmaceuticals Stock Rises 19% After Reporting Possible Underdiagnosis Of Babesiosis-
22.04.Sixty Degrees Pharmaceuticals: Babesiosis Disease Burden in United States is Substantially Higher Than Official Estimates, According to Preliminary Results of 60 Degrees Pharma Survey4
10.04.Why 60 Degrees Pharmaceuticals, Inc. (SXTP) Went Down On Thursday?2
09.04.60 Degrees and Yale to progress tafenoquin for babesiosis1
09.04.60 DEGREES PHARMACEUTICALS, INC. - 8-K, Current Report1
08.04.60 Degrees Pharmaceuticals kooperiert mit Yale für Arzneimittelentwicklung1
08.04.60 Degrees Pharmaceuticals partners with Yale for drug development1
28.03.60 Degrees Pharmaceuticals GAAP EPS of -$18.551
28.03.60 Degrees Pharmaceuticals Announces 2024 Annual Results114FY 2024 net product revenues increased 140% to $607.6 thousand.FY 2024 gross profit increased $443.8 thousand from ($221 thousand) to $222.8 thousand. WASHINGTON, March 28, 2025 (GLOBE NEWSWIRE) --...
► Artikel lesen
27.03.60 DEGREES PHARMACEUTICALS, INC. - S-1/A, General form for registration of securities1
27.03.60 DEGREES PHARMACEUTICALS, INC. - 10-K, Annual Report1
21.02.60 Degrees Pharmaceuticals and Fathom Holdings Interviews to Air on the RedChip Small Stocks, Big Money Show on Bloomberg TV434ORLANDO, FL / ACCESS Newswire / February 21, 2025 / RedChip Companies will air interviews with 60 Degrees Pharmaceuticals, Inc. (Nasdaq:SXTP) and Fathom Holdings Inc. (Nasdaq:FTHM) on the RedChip Small...
► Artikel lesen
Weiter >>
51 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1